A Phase 3 interventional study of RP-G28 and Placebos in Lactose Intolerance, sponsored by Ritter Pharmaceuticals, Inc.. Completed at 35 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-07-08.
Sponsored by Ritter Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study conducted in the United States (US) to assess the efficacy of RP-G28 compared to placebo on symptom reduction related to lactose intolerance.
Exclusion Criteria:
galacto-oligosaccharide, spray-dried powder for reconstitution for oral administration, 7.5 grams 2 times per day
Drug: RP-G28
maltodextrin, powder for reconstitution for oral administration, 7.5 grams 2 times per day
Drug: Placebos
powder for reconstitution for oral administration
powder for reconstitution for oral administration
Change from baseline of the Lactose Intolerance (LI) symptom composite score compared to placebo
Change from baseline of the LI symptom composite score compared to placebo. The LI symptom composite score includes abdominal pain, abdominal bloating, abdominal cramping, and abdominal gas.
Time frame: Day 61
Proportion of patients with a meaningful reduction in LI composite score.
Proportion of patients with a meaningful reduction in LI composite score. The LI symptom composite score includes abdominal pain, abdominal bloating, abdominal cramping, and abdominal gas.
Time frame: Day 61
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ritter Pharmaceuticals, Inc.